The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases

International Journal of Rheumatic Diseases

Volumn 15, Issue 3, 2012, Pages 249-260

  Chitra, Selvarajan ^a   Nalini, Ganesan ^a   Rajasekhar, Gopalakrishnan ^a  

^a SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

26S proteasome; Proteasome inhibitors; Ubiquitin proteasome system

Indexed keywords

AM 114; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CALPAIN; CARFILZOMIB; DELANZOMIB; EPOXOMICIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN; LACTACYSTIN BETA LACTONE; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; TP 110; UBIQUITIN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BRAIN PROTECTION; COMPLEX FORMATION; HUMAN; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; STROKE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; CELL PROLIFERATION; HUMANS; INFLAMMATION MEDIATORS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84862529832     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2012.01737.x     Document Type: Review

References (111)

1. Goldberg AL, Stein R, Adams J (1995) New insights into proteasome function: from Archaebacteria to drug development. Chem Biol 2, 503-8.
2. Coux O, Tanaka K, Goldberg AL (1996) Structure and function of the 20S and 26S proteasomes. Annu Rev Biochem 65, 801-47.
3. King RW, Deshaies RJ, Peters JM, Kirschner M (1996) How proteolysis drives the cell cycle. Science (Washington DC) 274, 1652-9.
4. Chau V, Tobia JW, Bachmair A et al. (1989) A multiubiquitin chain is confined to specific lysine in a targeted Short-lived protein. Science (Washington DC) 243, 1576-83.
5. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82, 373-428.
6. Ciechanover A, Orian A, Schwartz AL (2000) Ubiquitin-mediated proteolysis: biological regulation via destruction. BioEssays 22, 442-51.
7. Goldberg AL, Elledge SJ, Harper JW (2001) The cellular chamber of doom. Scientific Am 284, 68-73.
8. Nawaz Z, O'Malley BW (2004) Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription? Molec Endocrinol 18, 493-9.
9. Adams J, Palombella VJ, Elliott PJ (2000) Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 18, 109-21.
10. Adams J (2002) Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 6, 493-500.
11. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67, 425-79.
12. Varshavsky A (1997) The ubiquitin system. Trend Biochem Sci 22, 383-7.
13. Palombella VJ, Rando OJ, Goldberg AL et al. (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78, 773-85.
14. Palombella VJ, Conner EM, Fuseler JW et al. (1998) Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 95, 15671-6.
15. Schwartz AL, Ciechanover A (1999) The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 50, 57-74.
16. Ciechanover A, Brundin P (2003) The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40, 427-46.
17. Ohta T, Fukuda M (2004) Ubiquitin and breast cancer. Oncogene 23, 2079-88.
18. Etlinger JD, Goldberg AL (1977) A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc Natl Acad Sci U S A 74, 54-8.
19. Ciechanover A, Hod Y, Hershko A (1978) A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun 81, 1100-5.
20. Fang S, Weissman AM (2004) A field guide to ubiquitylation. Cell Mol Life Sci 61, 1546-61.
21. Hershko A, Heller H, Elias S, Ciechanover A (1983) Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem 258, 8206-14.
22. Meiners S, Ludwig A, Stangl V, Stangl K (2008) Proteasome inhibitors: poisons and remedies. Med Res Rev 28, 309-27.
23. Powell SR (2006) The ubiquitin-proteasome system in cardiac physiology and pathology. Am J Physiol Heart Circ Physiol 291, H1-19.
24. Hoffman L, Rechsteiner M (1996) Regulatory features of multicatalytic and 26S proteases. Curr Top Cell Regul 34, 1-32.
25. Voges D, Zwickl P, Baumeister W (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68, 1015-68.
26. Pickart CM, Cohen RE (2004) Proteasomes and their kins: proteases in the machine age. Nat Rev Mol Cell Biol 5, 177-87.
27. Finley D (2009) Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem 78, 477-513.
28. Groll M, Bochtler M, Brandstetter H, Clausen T, Huber R (2005) Molecular machines for protein degradation. ChemBioChem 6, 222-56.
29. Nickell S, Beck F, Scheres SH et al. (2009) Insights into the molecular architecture of the 26S proteasome. Proc Natl Acad Sci USA 106, 11943-7.
30. Zwickl P, Voges D, Baumeister W (1999) The proteasome: a macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond B Biol Sci 354, 1501-11.
31. Kloetzel PM (2001) Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2, 179-87.
32. DeMartino GN, Slaughter CA (1999) The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 274, 22123-6.
33. Baumeister W, Walz J, Zuhl F, Seemuller E (1998) The proteasome: paradigm of a self-compartmentalizing protease. Cell 92, 367-80.
34. Tanahashi N, Murakami Y, Minami Y, Shimbara N, Hendil KB, Tanaka K (2000) Hybrid proteasomes. Induction by interferon-gamma and contribution to ATP-dependent proteolysis. J Biol Chem 275, 14336-45.
35. Ciechanover A (1998) The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 17, 7151-60.
36. Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8, 739-58.
37. Rivett AJ (1993) Proteasomes: multicatalytic proteinase complexes. Biochem J 291, 1-10.
38. Goldberg AL (1995) Functions of the proteasome: the lysis at the end of the tunnel. Science 268, 522-3.
39. Rock KL, Gramm C, Rothstein L et al. (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78, 761-71.
40. Mitchell BS (2003) The proteasome - an emerging therapeutic target in cancer. N Engl J Med 348, 2597-8.
41. Hershko A, Ciechanover A, Varshavsky A (2000) Basic medical research award. The ubiquitin system. Nat Med 6, 1073-81.
42. Dou QP, Li B (1999) Proteasome inhibitors as potential novel anticancer agents. Drug Resist Update 2, 215-23.
43. An B, Goldfarb RH, Siman R, Dou QP (1998) Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 5, 1062-75.
44. Grimm LM, Goldberg AL, Poirier GG, Schwartz LM, Osborne BA (1996) Proteasomes play an essential role in thymocyte apoptosis. EMBO J 15, 3835-44.
45. Lee DH, Goldberg AL (1998) Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 8, 397-403.
46. Li B, Dou QP (2000) Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 97, 3850-5.
47. Adams J (2001) Proteasome inhibition in cancer: development of PS-341. Semin Oncol 28, 613-19.
48. Hideshima T, Richardson P, Chauhan D et al. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61, 3071-6.
49. Beg AA, Baltimore D (1996) An essential role for NF-kB in preventing TNF-induced cell death. Science (Washington DC), 274, 782-4.
50. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM (1996) Suppression of TNF-a-induced apoptosis by NF-κB. Science (Washington DC), 274, 787-9.
51. Wang CY, Mayo MW, Baldwin AS (1996) TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kB. Science (Washington DC), 274, 784-7.
52. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW (1997) Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kB control. Proc Natl Acad Sci USA 94, 10057-62.
53. Groll M, Kim KB, Kairies N, Huber R, Crews CM (2000) Crystal structure of epoxomicin: 20S proteasome reveals a molecular bassifor selectivity of alpha 'beta' - epoxyketone proteasome inhibitors. J Am Chem Soc 122, 1237-8.
54. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activit. Proc Natl Acad Sci USA 96, 10403-8.
55. Oikawa T, Sasaki T, Nakamura M et al. (1998) The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 246, 243-8.
56. Drexler HC, Risau W, Konerding MA (2000) Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 14, 65-77.
57. Adams J, Behnke M, Chen S et al. (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8, 333-8.
58. Adams J (2002) Development of the proteasome inhibitor PS-341. Oncologist 7, 9-16.
59. Orlowski RZ, Eswara JR, Lafond-Walker A et al. (1998) Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58, 4342-8.
60. Drexler HC (1997) Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 94, 855-60.
61. Delic J, Masdehors P, Omura S et al. (1998) The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 77, 1103-7.
62. Adams J, Palombella VJ, Sausville EA et al. (1999) Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59, 2615-22.
63. Almond JB, Cohen GM (2002) The proteasome: a novel target for cancer chemotherapy. Leukemia 16, 433-43.
64. Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5, 417-21.
65. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78, 773-85.
66. Pahl HL (1999) Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18, 6853-66.
67. Traenckner EB, Wilk S, Baeuerle PA (1994) A proteasome inhibitor prevents activation of NFkappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 13, 5433-41.
68. Mori S, Tanaka K, Omura S, Saito Y (1995) Degradation process of ligand-stimulated plateletderived growth factor beta-receptor involvesubiquitin-proteasome proteolytic pathway. J Biol Chem 270, 29447-52.
69. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, Kikuchi H (1995) Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 217, 1070-7.
70. Shinohara K, Tomioka M, Nakano H, Tone S, Ito H, Kawashima S (1996) Apoptosis induction resulting from proteasome inhibition. Biochem J 317, 385-8.
71. Tanimoto Y, Onishi Y, Hashimoto S et al. (1997) Peptidyl aldehyde inhibitors of proteasome induce apoptosis rapidly in mouse lymphoma RVC cells. J Biochem 121, 542-9.
72. Demo SD, Kirk CJ, Aujay MA et al. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67, 6383-91.
73. Yong Hwan H (2010) MG132 as a proteasome inhibitor induces cell growth inhibition and cell death in A549 lung cancer cells via influencing reactive oxygen species and GSH level. Hum Exp Toxicol 29, 607-14.
74. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL (1995) Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268, 726-31.
75. Bross PF, Kane R, Farrell AT et al. (2004) Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 10, 3954-64.
76. Jagannath S, Barlogie B, Berenson J et al. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127, 165-72.
77. Elliott PJ, Ross JS (2001) The proteasome: a new target for novel drug therapies. Am J Clin Pathol 116, 637-46.
78. Doherty FJ, Dawson S, Mayer RJ (2002) The ubiquitin-proteasome pathway of intracellular proteolysis. Essays Biochem 38, 51-63.
79. Goldberg AL, Rock K (2002) Not just research tools - proteasome inhibitors offer therapeutic promise. Nat Med 8, 338-40.
80. Hayashi T, Faustman D (2000) The role of the proteasome in autoimmunity. Diabetes Metab Res Rev 16, 325-37.
81. Wu J (2002) On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants. Am J Transplant 2, 904-12.
82. Grisham MB, Palombella VJ, Elliott PJ et al. (1999) Inhibition of NF-κB activation in vitro and in vivo: role of 26S proteasome. Methods Enzymol 300, 345-63.
83. Bo Kim K, Fonseca FN, Crews CM (2005) Development and characterization of proteasome inhibitors. Methods Enzymol 399, 585-609.
84. Crews CM (2003) Feeding the machine: mechanisms of proteasomecatalyzed degradation of ubiquitinated proteins. Curr Opin Chem Biol 7, 534-9.
85. Feldmann M, Andreakos E, Smith C et al. (2002) Is NF-κB a useful therapeutic target in rheumatoid arthritis?. Ann Rheum Dis 61(Suppl.2), ii13-8.84.
86. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T (1995) The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2, 493-506.
87. Cromartie WJ, Craddock JG, Schwab JH, Anderle SK, Yang CH (1977) Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med 146, 1585-602.
88. Miagkov AV, Kovalenko DV, Brown CE et al. (1998) NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 95, 13859-64.
89. Stansfield WE, Moss NC, Willis MS, Tang R, Selzman CH (2007) Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury. Ann Thorac Surg 84, 120-5.
90. Roodman GD (2008) Bone building with bortezomib. J Clin Invest 118, 462-4.
91. Debiasi RL, Squier MKT, Pike B et al. (1999) Reovirus-Induced Apoptosis Is Preceded by Increased Cellular Calpain Activity and Is Blocked by Calpain Inhibitors. J Virology 73, 695.
92. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W (2003) Salinosporamide A, an antitumor proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed 115, 369-71.
93. Macherla VR, Mitchell SS, Manam RR et al. (2005) Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 48, 3684-7.
94. Williamson MJ, Blank JL, Bruzzese FJ et al. (2006) Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Mol Cancer Ther 5, 3052-61.
95. Dorsey BD, Iqbal M, Chatterjee S et al. (2008) Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 51, 1068-7298.
96. Piva R, Ruggeri B, Williams M et al. (2008) CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111, 2765-75.
97. Kudo Y, Takata T, Ogawa I et al. (2000) P27Kip1 Accumulation by Inhibition of proteasome Function Induces Apoptosis in Oral Squamous Cell Carcinoma Cells. Clin Cancer Res 6, 916.
98. Zhang L, Zhang ZG, Zhang R, Chopp M, Adams J, Elliott PJ (2001) Postischemic (6h) treatment with rht-PA and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 32, 2926-31.
99. Williams AJ, Hale S, Moffett J, Adams J, Elliott PJ, Tortella FC (2003) Delayed treatment with MLN519 reduces infarction and associated neurological deficit caused by focal ischemic brain injury in rats via anti-inflammatory mechanisms involving NF-kB activation, gliosis and leukocyte infiltration. J Cereb Blood Flow Metabol 23, 75-87.
100. Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J (1999) Proteasome inhibition: a novel mechanism to combat asthma. J Allergy Clin Immunol 104, 294-300.
101. Vanderlugt CL, Rahbe SM, Elliott PJ, Dal Canto MC, Miller SD (2000) Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun 14, 205-11.
102. Brun J (2008) Proteasome inhibition as a novel therapy in treating rheumatoid arthritis. Medical Hypothesis 71, 65-72.
103. Iijima M, Momose I, Ikeda D (2009) TP 110, a New proteasome inhibitor, down regulates IAPs in human multiple myeloma cells. Anti cancer Res 29, 977-85.
104. Yannaki E, Papadopoulou A, Athanasiou E, Kaloyannidis P (2010) The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant induced arthritis in rats. Arthritis Rheum 62, 3277-88.
105. Ahmed AS, Li J, Ahmed M et al. (2010) Attenuation of Pain and inflammation in Adjuvant-Induced Arthritis by the Proteasome Inhibitor MG132. Arthrits Rheum 62, 2160-9.
106. Polzer K, Neubert K, Meister S et al. (2011) Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis. Arthritis Rheum 63, 670-80.
107. Ahn KS, Sethi G, Chao TH et al. (2007) Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappa B-regulated gene products. Blood, 110, 2286-95.
108. Miller CP, Ban K, Dujka ME et al. (2007) NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemic cells. Blood, 110, 267-77.
109. Achanta G, Modzelewska A, Feng L, Khan SR, Huang P (2006) A Boronic-Chalcone Derivative Exhibits Potent Anticancer Activity through Inhibition of the proteasome. Mol Pharmacol 70, 426-33.
110. Vasanthi P, Nalini G, Rajasekhar G (2008) Polymorphism of Tumour Necrosis Factor-α and its Plasma Levels in South Indian Population. Paper presented at IFCC-World Lab Fortaleza 2008, 28 September-2 October, Fortaleza, Brazil.
111. Nalini G, Vasanthi P, Rajasekhar G (2010) Signal transduction pathways in Rheumatoid arthritis. SRJM 3, 18-21.